Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Phathom Pharmaceuticals (PHAT) Income from Continuing Operations (2022 - 2026)

Phathom Pharmaceuticals (PHAT) has disclosed Income from Continuing Operations for 5 consecutive years, with 29538000.0 as the latest value for Q1 2026.

  • For Q1 2026, Income from Continuing Operations rose 68.67% year-over-year to 29538000.0; the TTM value through Mar 2026 reached 156302000.0, up 54.8%, while the annual FY2025 figure was 221057000.0, 33.88% up from the prior year.
  • Income from Continuing Operations hit 29538000.0 in Q1 2026 for Phathom Pharmaceuticals, down from 21143000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 21143000.0 in Q4 2025 and bottomed at 94294000.0 in Q1 2025.
  • Average Income from Continuing Operations over 5 years is 57878294.12, with a median of 51080000.0 recorded in 2022.
  • Year-over-year, Income from Continuing Operations plummeted 123.2% in 2024 and then skyrocketed 71.62% in 2025.
  • Phathom Pharmaceuticals' Income from Continuing Operations stood at 54957000.0 in 2022, then crashed by 44.76% to 79556000.0 in 2023, then grew by 6.36% to 74500000.0 in 2024, then surged by 71.62% to 21143000.0 in 2025, then tumbled by 39.71% to 29538000.0 in 2026.
  • According to Business Quant data, Income from Continuing Operations over the past three periods came in at 29538000.0, 21143000.0, and 29966000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.